MedTrace Logo

Study of Tislelizumab in Participants With Resectable Esophageal Squamous Cell Carcinoma

NCT04974047 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2025-12-01

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the pathological complete response (pCR) in participants receiving tislelizumab plus chemotherapy/chemoradiotherapy as neoadjuvant treatment.

Conditions

  • Resectable Esophageal Squamous Cell Carcinoma

Interventions

DRUG

Tislelizumab

Administered intravenously on Day 1 of each 21-Day Cycle.

DRUG

Paclitaxel

135 mg/m\^2 administered intravenously on Day 1 of each 21-Day Cycle.

DRUG

Cisplatin

80 mg/m\^2 administered intravenously on Day 1 of each 21-Day Cycle.

DRUG

5-fluorouracil

1000 mg/m\^2 administered intravenously over Day 1 through 4 of each 21-Day Cycle.

RADIATION

Radiotherapy

40 grays/20 fractions

PROCEDURE

Surgical resection

Performed as indicated in the treatment arm.

Sponsors & Collaborators

  • BeiGene

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-17
Primary Completion
2023-04-17
Completion
2024-10-25

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04974047 on ClinicalTrials.gov